{"title":"PBM整合:更好的定价还是更少的竞争?包括生物制剂在内的特种药品的增长，正迫使支付者和雇主考虑管理这些药品的成本节约策略。如果只有一家大型药品管理公司统治专业药房网络，他们将如何做到这一点?","authors":"Ed Silverman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>While the ramifications of Express Scripts' planned takeover of Medco are being debated, the use of pharmacy benefit managers is being questioned as cost savings decline and transparency issues hang high. And payers and employers still can't get rid of a \"bad taste in the mouth.\" So what does a mega PBM hope to accomplish?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"9 1","pages":"10-4"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351886/pdf/bh0901010.pdf","citationCount":"0","resultStr":"{\"title\":\"PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?\",\"authors\":\"Ed Silverman\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>While the ramifications of Express Scripts' planned takeover of Medco are being debated, the use of pharmacy benefit managers is being questioned as cost savings decline and transparency issues hang high. And payers and employers still can't get rid of a \\\"bad taste in the mouth.\\\" So what does a mega PBM hope to accomplish?</p>\",\"PeriodicalId\":89534,\"journal\":{\"name\":\"Biotechnology healthcare\",\"volume\":\"9 1\",\"pages\":\"10-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351886/pdf/bh0901010.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?
While the ramifications of Express Scripts' planned takeover of Medco are being debated, the use of pharmacy benefit managers is being questioned as cost savings decline and transparency issues hang high. And payers and employers still can't get rid of a "bad taste in the mouth." So what does a mega PBM hope to accomplish?
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
